The present disclosure generally relates to an antisense approach to prevent and/or reverse an autoimmune diabetes condition in NOD mice. This includes microsphere delivery of AS-oligonucleotides by injection to achieve therapeutic effect that causes a negative modulating activity, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres are fabricated using totally aqueous conditions, which microspheres incorporate one or more antisense (AS) oligonucleotides.
Microparticles, microspheres, and microcapsules are solid or semi-solid particles having a diameter of less than one millimeter, and may be less than 100 microns, which can be formed of a variety of materials, including synthetic polymers, proteins, and polysaccharides. Microspheres have been used in many different applications, primarily separations, diagnostics, and drug delivery.
A number of different techniques can be used to make these particles from synthetic polymers, natural polymers, proteins and polysaccharides, including phase separation, solvent evaporation, emulsification, and spray drying. Generally the polymers form the supporting structure of these microspheres, and the drug of interest is incorporated into the polymer structure. Exemplary polymers used for the formation of microspheres include homopolymers and copolymers of lactic acid and glycolic acid (PLGA) as described in U.S. Pat. No. 5,213,812 to Ruiz, U.S. Pat. No. 5,417,986 to Reid et al., U.S. Pat. No. 4,530,840 to Tice et al., U.S. Pat. No. 4,897,268 to Tice et al., U.S. Pat. No. 5,075,109 to Tice et al., U.S. Pat. No. 5,102,872 to Singh et al., U.S. Pat. No. 5,384,133 to Boyes et al., U.S. Pat. No. 5,360,610 to Tice et al., and European Patent Application Publication Number 248,531 to Southern Research Institute; block copolymers such as such as Tetronic®908 and poloxamer 407 as described in U.S. Pat. No. 4,904,479 to Illum; and polyphosphazenes as described in U.S. Pat. No. 5,149,543 to Cohen et al. Microspheres produced using polymers such as these exhibit a poor loading efficiency and are often only able to incorporate a small percentage of the drug of interest into the polymer structure. Therefore, substantial quantities of these types of microspheres often must be administered to achieve a therapeutic effect. In addition, these polymers typically are hydrophobic, negatively impacting the dissolution of the drug of interest. Polymers typically used in this context include polylactic glycolic acid (PLGA).
An objective for the medical community is the delivery of nucleic acids to the cells in an animal for treatment of various diseases including diabetes. In many approaches, nucleic acids can be delivered to cells in culture (in vitro) relatively efficiently with the addition of transfection agents. In addition, in vivo, the presence of endogenous nucleases results in a high rate of nucleic acid degradation when nucleic acid is delivered to animals.
In addition to protecting nucleic acid from nuclease digestion, a nucleic acid delivery vehicle must exhibit low toxicity, must be efficiently taken up by cells and have a well-defined, readily manufactured formulation. As shown in clinical trials, viral vectors for delivery can result in a severely adverse, even fatal, immune response in vivo. In addition, this method has the potential to have mutagenic effects in vivo. Delivery by complexing nucleic acids in lipid complexes of different formulations (such as liposomes or cationic lipid complexes) can have toxic effects. Complexes of nucleic acids with various polymers or with peptides have shown inconsistent results and the toxicity of these formulations has not yet been resolved. Nucleic acids also have been encapsulated in polymer matrices for delivery, but in these cases the particles have a wide size range and the effectiveness for therapeutic applications has not yet been demonstrated. Such previous approaches can yield effects that are the opposite of a goal desired herein, including stimulation of the immune system. For example, when PLGA is incorporated into particles, the immune system is stimulated by the presence of the PLGA.
Therefore, there is a need for addressing the issues in the delivery of nucleic acids, and there is an ongoing need for development of microspheres and new methods for making microspheres. Details regarding microspheres, especially details regarding their preparation and properties, are found in U.S. Pat. No. 6,458,387 to Scott et al., U.S. Pat. Nos. 6,268,053, 6,090,925, 5,981,719 and 5,599,719 to Woiszwillo et al., and U.S. Pat. No. 5,578,709 to Woiszwillo and US Patent Application Publication No. 2006/0024240 to Brown et al. These and all references identified herein are incorporated by reference hereinto.
In accordance with the present disclosure, oligonucleotides are delivered as microspheres. It is believed that such a delivery approach prevents access of the nucleases to the nucleic acids within the microsphere. Microsphere delivery of antisense (AS) oligonucleotides is carried out in order to induce dendritic cell tolerance, particularly in the NOD mouse model. The microspheres are fabricated using aqueous conditions such that antisense (AS) oligonucleotides are incorporated. These microspheres are used to inhibit gene expression and to prevent and/or reverse an autoimmune diabetes condition in NOD mice in vivo.
In a one aspect of the disclosure, three AS-oligonucleotides targeted to the CD40, CD80 and CD86 transcripts are synthesized, and an aqueous solution of the oligonucleotide mixture is prepared and combined with an aqueous polymer solution. Microspheres containing the oligonucleotides are formed, and these are delivered to the NOD mice by injection.
In one aspect of the disclosure, there is provided a method for reversing type 1 diabetes in a mammal comprising administering a microsphere composition wherein microspheres in the composition comprise oligonucleotides that are antisense to and targeted to bind to primary transcripts selected from the group consisting of CD40, CD80 and CD86 primary transcripts and combinations thereof. The oligonucleotides can be selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and combinations thereof, or indeed any other oligonucleotides that target CD40, CD80 and CD86.
Another aspect of the disclosure is directed to a method of protecting beta cells of the pancreas of a mammal from autoimmune destruction, comprising injecting into the mammal a microsphere composition, wherein the microspheres in the composition comprise oligonucleotides that are antisense to and targeted to bind to primary transcripts selected from the group consisting of CD40, CD80 and CD86 primary transcripts and combinations thereof.
Another aspect is a method of decreasing T-cell-mediated inflammation of the pancreas and/or pancreatic beta cell death in a mammal comprising administering to the mammal a microsphere composition, wherein the microspheres in the composition comprise oligonucleotides that are antisense to and targeted to bind to primary transcripts selected from the group consisting of CD40, CD80 and CD86 primary transcripts, and combinations thereof, wherein the composition is administered in an amount effective to ameliorate the symptoms of Type 1 diabetes in the mammal. In more defined aspects, the composition is administered after clinical onset of Type 1 diabetes. In alternative aspects, the composition is administered prior to clinical onset of Type 1 diabetes. In these therapeutic aspects, the administration of the composition normalizes blood glucose levels in the mammal as compared to the blood glucose levels of the mammal prior to administration.
The administration of the composition may regenerate the beta cell population of the mammal or halt the further deterioration of the beta cell population or both.
The composition may be administered in any form and in certain exemplary aspects is administered as an injectable form. In specific aspects, the composition is administered in combination with insulin. Where a combination therapy is used, the insulin may be administered prior to, concurrently with, or after administration of the microsphere composition.
Additional aspects are directed to methods of preserving residual beta cell mass in a subject with new-onset or preclinical autoimmune diabetes comprising administering to the subject a composition containing microspheres comprising oligonucleotides that are antisense to and targeted to bind to CD40, CD80 and CD86 primary transcripts, wherein administration of the composition maintains the beta cell mass of the mammal to at least about 15% of the mass present prior to diabetes onset. The subject may be a human subject. The subject may be a human child. The treatment method may involve repeated administration of the composition and the repeated administration increases the beta cell mass of the mammal.
In particular defined methods, 30% and as much as 70% w/w of the microspheres is oligonucleotide. Such compositions typically may comprise a ratio in the microsphere composition of antisense CD40:antisense CD80: antisense CD86 of 1:1:1.
These and other aspects, objects, features and advantages of the present disclosure, including the various combinations, will be apparent from and clearly understood through a consideration of the following detailed description.
In the course of this description, reference will be made to the attached drawings, wherein:
a and 1b are scanning electron micrographs of microspheres of AS-oligonucleotides and poly-L-lysine polycation.
a and 2b are graphs showing the properties of a microsphere preparation according to the disclosure.
a-6d are light micrographs of pancreatic tissue sections from control NOD mice stained with haemotoxylin and eosin (
a-7d are light micrographs of pancreatic tissue sections from AS-MSP treated NOD mice stained with haemotoxylin and eosin (
As required, detailed embodiments of the present disclosure are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the disclosure, which may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present disclosure in virtually any appropriate manner.
Type I diabetes is an autoimmune disorder where there is a progressive inflammation of the pancreas, and specifically, the endocrine insulin-producing beta cells. Before onset, the inflammation first renders the endocrine beta cells dysfunctional. A single injection of a microsphere formulation considerably delays disease onset in the non-obese diabetic (NOD) mouse model of human autoimmune (type 1) diabetes. Although not wishing to be bound by any particular theory, it is believed the microspheres are taken up by resident and migrating dendritic cells at the site of injection and then move into the proximal lymph nodes before onset of the disease. It is also believed that a decreased proliferation of T-cells targeted to putative beta cell antigens in vitro occurs in treated recipients. An increase may occur in the prevalence of CD4+CD25+ putative T regulatory cells in immunodeficient NOD-scid mice reconstituted with syngeneic T-cells and dendritic cells and then administered the microspheres. Thus, a microsphere-based therapeutic composition can modulate dendritic cell activity and mobilize regulatory networks for prophylaxis.
It would be desirable to have a treatment that would prevent the onset of diabetes. It would also be desirable to have a therapeutic composition that would arrest or reverse the disease after clinical onset when a substantial number of beta cells have been destroyed. Repeated administration into new-onset diabetic mice normalizes hyperglycemia and reverses the disease. Reversal typically indicates having the individual, such as a human or other mammal, exhibit near normalization of blood glucose levels. Without being bound by any particular theory, it is believed that during “reversal”, disease-induced T-cell inflammation and cell death are resisted.
One embodiment reverses autoimmune insulin-dependent diabetes by formulating and injecting antisense (AS)-oligonucleotide microspheres described herein, targeting the transcripts of CD40, CD80 and CD86. Specific examples of antisense oligonucleotides directed against the transcripts are disclosed in the Examples hereof. It will be understood that other antisense oligonucleotides may be designed to be effective in binding the CD40, CD80 and CD86 transcripts to achieve the effects described herein. It will also be understood that such oligonucleotides may incorporate modifications known in the art including, but not limited to, thioation, methylation and methoxyethylation and that the location and number of such modifications may be varied to achieve an optimal effect. These oligonucleotides are designed to induce immune tolerance that results in the reversal of the destruction of the insulin producing beta cells in the NOD mouse model.
Type 1 diabetes is manifested by the autoimmune destruction of the pancreatic insulin-producing beta cells in the NOD mouse, as well as in humans. At the time of clinical onset, humans typically have 10-20% or less of residual beta cell mass. Sparing of any of this residual mass can result in remaining insulin levels which are adequate to regulate glucose levels. In addition, reversing the destruction of beta cells may result in the partial regeneration of the beta cell population. The oligonucleotide-containing microparticles of the present disclosure are provided to interfere with the autoimmune destruction of the beta cells.
It will be appreciated that dendritic cells (DC) can be activated to be potent antigen-presenting cells found in all tissues and which are present under the skin. These antigen-presenting dendritic cells function as triggers of the immune response, including autoimmune responses, through the activation of T-cells, particularly in lymph nodes. Although not wishing to be bound by theory, CD40, CD80 and CD86 are believed to be important for the autoimmune response, and the downregulation of these molecules is thought to promote autoimmune hyporesponsiveness. In addition, certain cytokines, such as interferons and interleukins, are reduced as a result of the hyporesponsiveness.
In making the microspheres that are used for treatment of autoimmune diabetes in mice, one, two or three AS-oligonucleotides may be dissolved in aqueous solution and combined with water soluble polymer(s) and a polycation. The solution typically is incubated at about 60-70° C., cooled to about 23° C., and the excess polymer is removed.
The nucleic acids typically comprise between about 30 and about 100 weight percent of the microspheres and have an average particle size of not greater than about 50 microns, typically not greater than about 20 microns, and can be not more than about 10 microns. Typically, they are prepared as follows. An aqueous solution of the oligonucleotide or oligonucleotides is prepared. When microspheres containing three oligonucleotides are to be prepared, aliquots from three oligonucleotide solutions are combined. Each solution contains one of these three oligonucleotide types. The final solution containing oligonucleotides typically contains about 10 mg/ml of oligonucleotide.
In specific examples, the microsphere formulation contains 65%, 70%, 75%, 80%, 85%, 90% w/w or greater load of oligonucleotides. In such embodiments, the compositions have a poly-L-lysine content of 6-10% w/w. in addition the moisture content of the microspheres varies and can be approximately 4%. The oligonucleotides are present in a ratio of 1:1:1 of antisense CD40:antisense CD80:antisense CD86.
These are combined with aliquots of a 10 mg/ml stock solution of polycation. Examples of polycations are poly-lysine and poly-ornithine. Others include polyethyleneimine (PEI), prolamine, protamine, polyvinyl pyrrolidone (PVP), polyarginine, vinylamine, and derivatives of positively-charged polysaccharides, such as positively charged chitosan, and combinations thereof. The polycation solution can be at volumetric ratios of polycation:oligonucleotide of from about 1:1 to about 4:1. Commonly used polycations include poly-L-lysine•HBr (up to 70,000 Daltons available from Bachem) and poly-L-omithine•HBr (e.g. 11,900 Daltons available from Sigma).
Polymer solutions also are prepared. These can function as phase-separation enhancing agents. Examples of suitable polymers include linear or branched polymers, copolymers and block copolymers. These polymers can be water soluble, semi-water soluble, water-miscible, or soluble in a water-miscible solvent. Examples of polymers include pharmaceutically acceptable additives such as polyethylene glycol (PEG) of various molecular weights, such as PEG 200, PEG 300, PEG 3350, PEG 8000, PEG 10000, PEG 20000, etc. and poloxamers of various molecular weights such as poloxamer 188 and Pluronic F127 or Pluronic F68. A commonly used polymer is polyvinylpyrrolidone (PVP). Another polymer is hydroxyethylstarch. Other amphiphilic polymers can also be used alone or in combinations. The phase-separation enhancing agent can also be a non-polymer such as a mixture of propylene glycol and ethanol.
In a typical embodiment, a polymer solution of polyvinyl pyrrolidone and/or of polyethylene glycol may be prepared and combined with the other solutions. Heating, cooling, centrifuging and washing multiple times provide an aqueous suspension which typically is frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and polycation.
The microspheres are suitable for in vivo delivery by an injectable route, including intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, epidural, intra-arterial, intra-articular and the like. Other delivery routes that can be practiced include such as topical, oral, rectal, nasal, pulmonary, vaginal, buccal, sublingual, transdermal, transmucosal, otic or intraocular.
Without being bound by any particular theory, it is believed that microspheres containing the antisense oligonucleotides exemplified herein down-regulate cell surface molecules CD40, CD80 and CD86. The microspheres are injected and dendritic cells are believed to actively uptake the oligonucleotide microspheres. These oligonucleotides suppress the expression of cell surface cell molecules CD40, CD80 and CD86 in dendritic cells. The administration of these antisense oligonucleotide microspheres after development in the NOD mouse effectively reverses diabetes.
The following Examples illustrate certain features and advantages of the disclosure in order to further illustrate the disclosure. The Examples are not to be considered limiting or otherwise restrictive of the disclosure.
Three AS-oligonucleotides targeted to the CD40, CD80 and CD86 primary transcripts were synthesized. The AS-oligonucleotide sequences used in this Example are, with asterisks indicating sites of thioation in the backbone:
An aqueous solution of the oligonucleotide mixture was prepared by combining aliquots of three oligonucleotide solutions, each of which contained one type of oligonucleotide, to form a 10 mg/ml solution of the three types of oligonucleotides. A 10 mg/ml solution of poly-L-lysine•HBr in deionized water (poly-L-lysine•HBr up to 70,000 Daltons, by Bachem, King of Prussia, Pa.) was prepared. The poly-L-lysine•HBr was added to the oligonucleotides solution at a volumetric ratio of 1:1. The mixture was vortexed gently. A 25% polymer solution containing 12.5% PVP (polyvinyl pyrrolidone, 40,000 Daltons, Spectrum Chemicals, Gardena, Calif.) and 12.5% PEG (polyethylene glycol, 3,350 Daltons, Spectrum Chemicals, Gardena, Calif.) in 1M Sodium Acetate (Spectrum, Gardena, Calif.) at pH5.5 was added in a 2:1 volumetric ratio as follows: 0.75 ml of AS-oligonucleotides, 0.75 ml of poly-L-lysine•HBr, 3.0 ml of PEG/PVP, and a total volume of 4.50 ml.
The batch was incubated for 30 minutes at 70° C. and then cooled to 23° C. Upon cooling, the solution became turbid and microspheres were formed. The suspension was then centrifuged, and the excess PEG/PVP was removed. The resulting pellet was washed by resuspending the pellet in deionized water, followed by centrifugation and removal of the supernatant. The washing process was repeated three times. The aqueous suspension was frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and poly-L-lysine.
a and b present representative scanning electron micrographs (SEM) of 1:1 poly-L-lysine: oligonucleotide ratio microspheres at two different magnifications. Microspheres, 0.5-4 μm in size, with an average particle size of approximately 2.5 μm were fabricated.
In this Example, the results of tests that cover prevention aspects of the disclosure are shown. As shown in
a and 6b show sections of pancreatic tissue from mice that received no treatment and thus progress spontaneously to autoimmunity (diabetic NOD mice) stained with haemotoxylin and eosin (H+E;
a and 7b shows sections of pancreatic tissue from mice treated when less than 8 weeks of age (prevention model) and treated with the antisense microspheres of the disclosure stained with haemotoxylin and eosin (H+E;
As shown in
As shown in
A major concern for eventual translation of diabetes-suppressive therapies into human trials is the antigen specificity (and therefore the cell specificity) of the treatment approach and whether the treatment confers global and non-specific suppression. To address these issues, randomly-selected diabetes-free mice were euthanised from the cohorts shown in
Furthermore, ascertaining the cytokine profile in the co-culture supernatants, we observed a significant decrease in TNFα production by T-cells from AS-MSP-treated, diabetes-free NOD mice even in the presence of NIT-1 lysate. Although IFNγ production was slightly decreased in the co-cultures of T-cells from the AS-MSP-treated mice, it was not statistically-distinguishable from the co-cultures with T-cells from PBS-treated mice in the presence of NIT-1 lysate. The assay, finally, could not detect the presence of IL-4, IL-10 or TGFfβ in the supernatants.
The ability of antisense oligonucleotide microspheres to reverse the symptoms of diabetes in early onset NOD mice was also tested. A timeline for these experiments is shown in
In
c and 7d show sections of pancreatic tissue from NOD mice that were treated with antisense formulations after onset of diabetes and showed reversal of the disease. The sections are stained with haemotoxylin and eosin (H+E;
3 different AS-oligonucleotides can be incorporated into PROMAXX microspheres and such microspheres can be used as a composition to prevent and/or reverse new onset autoimmune diabetes via immunoregulatory dendritic cell induction. Indeed, a single injection of the composition delayed disease onset and repeated administration into new-onset diabetic mice normalized hyperglycemia, suggesting reversal of disease. In these studies, insulin was administered daily until blood glucose fell below 300 mg/dL. Insulin then was stopped whereupon AS-MSP were administered subcutaneously. In an exemplary dosing regiment, the animals were administered 2 mg AS-MP per kg body weight two times a week for 3-4 weeks. The diabetes-free NOD mice were monitored.
In
A diagram showing the impact of therapeutic reversal of autoimmune diabetes is show in
It will be understood that the embodiments of the present disclosure which have been described are illustrative of some of the applications of the principles of the present disclosure. Numerous modifications may be made by those skilled in the art without departing from the true spirit and scope of the disclosure. Various features which are described herein can be used in any combination and are not limited to precise combinations which are specifically outlined herein.
The present application claims the benefit of priority of U.S. Provisional Application Ser. No. 60/835,742, which was filed Aug. 4, 2006 and U.S. Provisional Application Ser. No. 60/864,914, which was filed Nov. 8, 2006. The entire text of each of the aforementioned applications is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3737337 | Schnoring et al. | Jun 1973 | A |
3891570 | Fukushima et al. | Jun 1975 | A |
4389330 | Tice et al. | Jun 1983 | A |
4530840 | Tice et al. | Jul 1985 | A |
4584894 | Fogelberg | Apr 1986 | A |
4652441 | Okada et al. | Mar 1987 | A |
4728721 | Yamamoto et al. | Mar 1988 | A |
4818542 | DeLuca et al. | Apr 1989 | A |
4849228 | Yamamoto et al. | Jul 1989 | A |
4861627 | Mathiowitz et al. | Aug 1989 | A |
4897268 | Tice et al. | Jan 1990 | A |
4904479 | Illum et al. | Feb 1990 | A |
4917893 | Okada et al. | Apr 1990 | A |
5075109 | Tice et al. | Dec 1991 | A |
5102872 | Singh et al. | Apr 1992 | A |
5149543 | Cohen et al. | Sep 1992 | A |
5213812 | Ruiz | May 1993 | A |
5300464 | Rittler | Apr 1994 | A |
5330767 | Yamamoto et al. | Jul 1994 | A |
5330768 | Park et al. | Jul 1994 | A |
5360610 | Tice et al. | Nov 1994 | A |
5384133 | Boyes et al. | Jan 1995 | A |
5407609 | Tice et al. | Apr 1995 | A |
5417986 | Reid et al. | May 1995 | A |
5422120 | Kim | Jun 1995 | A |
5476663 | Okada et al. | Dec 1995 | A |
5480656 | Okada et al. | Jan 1996 | A |
5482927 | Maniar et al. | Jan 1996 | A |
5525519 | Woiszwillo | Jun 1996 | A |
5543158 | Gref et al. | Aug 1996 | A |
5554730 | Woiszwillo et al. | Sep 1996 | A |
5556642 | Kobayashi et al. | Sep 1996 | A |
5575987 | Kamei et al. | Nov 1996 | A |
5578709 | Woiszwillo | Nov 1996 | A |
5599719 | Woiszwillo et al. | Feb 1997 | A |
5603961 | Suzuki et al. | Feb 1997 | A |
5620883 | Shao et al. | Apr 1997 | A |
5631020 | Okada et al. | May 1997 | A |
5631021 | Okada et al. | May 1997 | A |
5643607 | Okada et al. | Jul 1997 | A |
5650173 | Ramstack et al. | Jul 1997 | A |
5654008 | Herbert et al. | Aug 1997 | A |
5654010 | Johnson et al. | Aug 1997 | A |
5665428 | Cha et al. | Sep 1997 | A |
5667808 | Johnson et al. | Sep 1997 | A |
5716640 | Kamei et al. | Feb 1998 | A |
5851451 | Takechi et al. | Dec 1998 | A |
5891478 | Johnson et al. | Apr 1999 | A |
5932248 | Chen et al. | Aug 1999 | A |
5945126 | Thanoo et al. | Aug 1999 | A |
5972707 | Roy et al. | Oct 1999 | A |
5981719 | Woiszwillo et al. | Nov 1999 | A |
5989463 | Tracy et al. | Nov 1999 | A |
5994314 | Eljamal et al. | Nov 1999 | A |
6020175 | Onda et al. | Feb 2000 | A |
6036976 | Takechi et al. | Mar 2000 | A |
6048550 | Chan et al. | Apr 2000 | A |
6051259 | Johnson et al. | Apr 2000 | A |
6063910 | Debenedetti et al. | May 2000 | A |
6077833 | Bennett et al. | Jun 2000 | A |
6090925 | Woiszwillo et al. | Jul 2000 | A |
6107084 | Onda et al. | Aug 2000 | A |
6120787 | Gustafsson et al. | Sep 2000 | A |
6140475 | Margolin et al. | Oct 2000 | A |
6153211 | Hubbell et al. | Nov 2000 | A |
6197584 | Bennett et al. | Mar 2001 | B1 |
6242230 | Batich et al. | Jun 2001 | B1 |
6252055 | Relton et al. | Jun 2001 | B1 |
6265389 | Burke | Jul 2001 | B1 |
6267958 | Andya et al. | Jul 2001 | B1 |
6268053 | Woiszwillo et al. | Jul 2001 | B1 |
6270795 | Jones et al. | Aug 2001 | B1 |
6270802 | Thanoo et al. | Aug 2001 | B1 |
6290991 | Roser et al. | Sep 2001 | B1 |
6303582 | Eljamal et al. | Oct 2001 | B1 |
6312727 | Schacht et al. | Nov 2001 | B1 |
6319906 | Bennett et al. | Nov 2001 | B1 |
6361798 | Thanoo et al. | Mar 2002 | B1 |
6395253 | Levy et al. | May 2002 | B2 |
6395302 | Hennink et al. | May 2002 | B1 |
6455074 | Tracy et al. | Sep 2002 | B1 |
RE37872 | Franks et al. | Oct 2002 | E |
6458387 | Scott et al. | Oct 2002 | B1 |
6475995 | Roy et al. | Nov 2002 | B1 |
6479146 | Caruso et al. | Nov 2002 | B1 |
6500448 | Johnson et al. | Dec 2002 | B1 |
6506410 | Park et al. | Jan 2003 | B1 |
6534483 | Bruno et al. | Mar 2003 | B1 |
6541606 | Margolin et al. | Apr 2003 | B2 |
6569458 | Gombotz et al. | May 2003 | B1 |
6596316 | Lyons et al. | Jul 2003 | B2 |
6616949 | Jonsson et al. | Sep 2003 | B2 |
6630169 | Bot et al. | Oct 2003 | B1 |
6645525 | Woiszwillo et al. | Nov 2003 | B1 |
RE38385 | Franks et al. | Jan 2004 | E |
6699501 | Neu et al. | Mar 2004 | B1 |
6713533 | Panzner et al. | Mar 2004 | B1 |
6749866 | Bernstein et al. | Jun 2004 | B2 |
6814980 | Levy et al. | Nov 2004 | B2 |
6830737 | Ramstack | Dec 2004 | B2 |
6833192 | Caruso et al. | Dec 2004 | B1 |
6849259 | Haurum et al. | Feb 2005 | B2 |
6861064 | Laakso et al. | Mar 2005 | B1 |
6875432 | Liu et al. | Apr 2005 | B2 |
7378095 | Cao et al. | May 2008 | B2 |
20010002261 | Morrison et al. | May 2001 | A1 |
20020009453 | Haurum et al. | Jan 2002 | A1 |
20020045571 | Liu et al. | Apr 2002 | A1 |
20020136719 | Shenoy et al. | Sep 2002 | A1 |
20020137156 | Margolin et al. | Sep 2002 | A1 |
20020146459 | Levy et al. | Oct 2002 | A1 |
20020187197 | Caruso et al. | Dec 2002 | A1 |
20020197325 | Osborne | Dec 2002 | A1 |
20030007990 | Blankenship et al. | Jan 2003 | A1 |
20030026844 | Lee et al. | Feb 2003 | A1 |
20030059474 | Scott et al. | Mar 2003 | A1 |
20030124368 | Lynn et al. | Jul 2003 | A1 |
20030129239 | Goldshtein | Jul 2003 | A1 |
20030137067 | Cooper et al. | Jul 2003 | A1 |
20030157181 | Panzner et al. | Aug 2003 | A1 |
20030175239 | Margolin et al. | Sep 2003 | A1 |
20030180370 | Lesniak et al. | Sep 2003 | A1 |
20030211153 | Johnson et al. | Nov 2003 | A1 |
20030236214 | Wolff et al. | Dec 2003 | A1 |
20040013721 | Antipov et al. | Jan 2004 | A1 |
20040013738 | Voigt et al. | Jan 2004 | A1 |
20040014698 | Hortelano et al. | Jan 2004 | A1 |
20040017018 | Pommersheim | Jan 2004 | A1 |
20040022081 | Erickson et al. | Feb 2004 | A1 |
20040043076 | Dulieu et al. | Mar 2004 | A1 |
20040047979 | Qiu et al. | Mar 2004 | A1 |
20040110898 | Dreja et al. | Jun 2004 | A1 |
20040185091 | Truong-Le et al. | Sep 2004 | A1 |
20040186071 | Bennett et al. | Sep 2004 | A1 |
20040197324 | Liu et al. | Oct 2004 | A1 |
20040202643 | Margolin et al. | Oct 2004 | A1 |
20040209804 | Govardhan et al. | Oct 2004 | A1 |
20040219224 | Yakovlevsky et al. | Nov 2004 | A1 |
20040241202 | Chluba et al. | Dec 2004 | A1 |
20040258762 | Boppart et al. | Dec 2004 | A1 |
20050048127 | Brown et al. | Mar 2005 | A1 |
20050053666 | Tzannis et al. | Mar 2005 | A1 |
20050142201 | Rashba-Step et al. | Jun 2005 | A1 |
20050142205 | Rashba-Step et al. | Jun 2005 | A1 |
20050142206 | Brown et al. | Jun 2005 | A1 |
20050147687 | Rashba-Step et al. | Jul 2005 | A1 |
20050158303 | Liu et al. | Jul 2005 | A1 |
20050170005 | Rashba-Step et al. | Aug 2005 | A1 |
20050175603 | Liu et al. | Aug 2005 | A1 |
20050180967 | Haurum et al. | Aug 2005 | A1 |
20050202072 | Ruch-Rasmussen et al. | Sep 2005 | A1 |
20050233945 | Brown et al. | Oct 2005 | A1 |
20050271732 | Seeney et al. | Dec 2005 | A1 |
20060002862 | Truong-Le et al. | Jan 2006 | A1 |
20060018971 | Scott et al. | Jan 2006 | A1 |
20060024240 | Brown et al. | Feb 2006 | A1 |
20060024379 | Brown et al. | Feb 2006 | A1 |
20060127395 | Arvinte et al. | Jun 2006 | A1 |
20060182740 | Yang et al. | Aug 2006 | A1 |
20060276425 | Mourich et al. | Dec 2006 | A1 |
20070023776 | Zakgeym et al. | Feb 2007 | A1 |
20070065440 | Tomlinson et al. | Mar 2007 | A1 |
20070122411 | Matheus et al. | May 2007 | A1 |
20070161589 | Bennett et al. | Jul 2007 | A1 |
20070172475 | Matheus et al. | Jul 2007 | A1 |
20070172479 | Warne et al. | Jul 2007 | A1 |
Number | Date | Country |
---|---|---|
04312970 | Oct 1994 | DE |
19812083 | Sep 1999 | DE |
10157799 | Sep 2002 | DE |
248531 | Dec 1987 | EP |
0377477 | Jul 1990 | EP |
0564061 | Oct 1993 | EP |
0647477 | Apr 1995 | EP |
809110 | Nov 1997 | EP |
0936902 | Aug 1999 | EP |
0957926 | Nov 1999 | EP |
0972563 | Jan 2000 | EP |
1060741 | Dec 2000 | EP |
1116516 | Jul 2001 | EP |
1173151 | Jan 2002 | EP |
1173550 | Jan 2002 | EP |
0975334 | Feb 2002 | EP |
1283720 | Feb 2003 | EP |
1801123 | Jun 2004 | EP |
1614751 | Jan 2006 | EP |
0907378 | Feb 2006 | EP |
08245815 | Sep 1996 | JP |
2006219455 | Aug 2006 | JP |
WO9107951 | Jun 1991 | WO |
WO-9314110 | Jul 1993 | WO |
WO-9418947 | Sep 1994 | WO |
WO-9420856 | Sep 1994 | WO |
WO-9424263 | Oct 1994 | WO |
WO-9500128 | Jan 1995 | WO |
WO-9603978 | Feb 1996 | WO |
WO-9608289 | Mar 1996 | WO |
WO-9745140 | Dec 1997 | WO |
WO-9947252 | Sep 1999 | WO |
WO-9947253 | Sep 1999 | WO |
WO-0003797 | Jan 2000 | WO |
WO-0028972 | May 2000 | WO |
WO-0041679 | Jul 2000 | WO |
WO-0062759 | Oct 2000 | WO |
WO-0077281 | Dec 2000 | WO |
WO-0128524 | Apr 2001 | WO |
WO-0151196 | Jul 2001 | WO |
WO-0164330 | Sep 2001 | WO |
WO-0189563 | Nov 2001 | WO |
WO-0209864 | Feb 2002 | WO |
WO-0209865 | Feb 2002 | WO |
WO-0217888 | Mar 2002 | WO |
WO-02072636 | Sep 2002 | WO |
WO-02074431 | Sep 2002 | WO |
WO-02096457 | Dec 2002 | WO |
WO-03000014 | Jan 2003 | WO |
WO-03015750 | Feb 2003 | WO |
WO-03030874 | Apr 2003 | WO |
WO-03043729 | May 2003 | WO |
WO-03087384 | Oct 2003 | WO |
WO-03090920 | Nov 2003 | WO |
WO-03097706 | Nov 2003 | WO |
WO-03099228 | Dec 2003 | WO |
WO-2004001007 | Dec 2003 | WO |
WO-2004030649 | Apr 2004 | WO |
WO-2004058156 | Jul 2004 | WO |
WO-2004060343 | Jul 2004 | WO |
WO-2004060920 | Jul 2004 | WO |
WO-2004100928 | Nov 2004 | WO |
WO-2005035088 | Apr 2005 | WO |
WO-2005051355 | Jun 2005 | WO |
WO-2005077414 | Aug 2005 | WO |
WO-2005008443 | Sep 2005 | WO |
WO-2005089727 | Sep 2005 | WO |
WO-2005012894 | Dec 2005 | WO |
WO-2005112885 | Dec 2005 | WO |
WO-2005112893 | Dec 2005 | WO |
WO-2005112894 | Dec 2005 | WO |
WO-2005123131 | Dec 2005 | WO |
WO-2006031560 | Mar 2006 | WO |
WO-2006065746 | Jun 2006 | WO |
WO-2006072527 | Jul 2006 | WO |
WO-2006112838 | Oct 2006 | WO |
WO-2007031333 | Mar 2007 | WO |
WO-2007076062 | Jul 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20080039369 A1 | Feb 2008 | US |
Number | Date | Country | |
---|---|---|---|
60835742 | Aug 2006 | US | |
60864914 | Nov 2006 | US |